Top

Cancer Cell International

Published in:

Open Access 01-12-2022 | Ovarian Cancer | Primary research

Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer

Authors: Leilei Liang, Jian Li, Jing Yu, Jing Liu, Lin Xiu, Jia Zeng, Tiantian Wang, Ning Li, Lingying Wu

Published in: Cancer Cell International | Issue 1/2022

Abstract

Background

Ovarian cancer (OC) is an invasive gynaecologic cancer with a high cancer-related death rate. The purpose of this study was to establish an invasion-related multigene signature to predict the prognostic risk of OC.

Methods

We extracted 97 invasion-related genes from The Cancer Genome Atlas (TCGA) database. Then, the ConsensusClusterPlus and limma packages were used to calculate differentially expressed genes (DEGs). To calculate the immune scores of the molecular subtypes, we used ESTIMATE to evaluate the stromal score, immune score and ESTIMATE score. MCP-counter and the GSVA package ssgsea were used to evaluate the types of infiltrating immune cells. Survival and nomogram analyses were performed to explore the prognostic value of the signature. Finally, qPCR, immunohistochemistry staining and functional assays were used to evaluate the expression and biological abilities of the signature genes in OC.

Results

Based on the consistent clustering of invasion-related genes, cases in the OC datasets were divided into two subtypes. A significant difference was observed in prognosis between the two subtypes. Most genes were highly expressed in the C1 group. Based on the C1 group genes, we constructed an invasion-related 6-gene prognostic risk model. Furthermore, to verify the signature, we used the TCGA-test and GSE32062 and GSE17260 chip datasets for testing and finally obtained a good risk prediction effect in those datasets. Moreover, the results of the qPCR and immunohistochemistry staining assays revealed that KIF26B, VSIG4 and COL6A6 were upregulated and that FOXJ1, MXRA5 and CXCL9 were downregulated in OC tissues. The functional study showed that the expression of KIF26B, VSIG4, COL6A6, FOXJ1, MXRA5 and CXCL9 can regulate the migration and invasion abilities of OC cells.

Conclusion

We developed a 6-gene prognostic stratification system (FOXJ1, MXRA5, KIF26B, VSIG4, CXCL9 and COL6A6) that is independent of clinical features. These results suggest that the signature could potentially be used to evaluate the prognostic risk of OC patients.

Available only for authorised users

Timmermans M, Sonke GS, Van de Vijver KK, Aa MA. No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2018;88:31–7. https://doi.org/10.1016/j.ejca.2017.10.030CrossRefPubMed

Sant M, Lopez M, Agresti R, Pérez M, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos K, Katalinic A, Langseth H. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer. 2015. https://doi.org/10.1016/j.ejca.2015.07.022.CrossRefPubMedPubMedCentral

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21456.CrossRefPubMedPubMedCentral

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:16061.CrossRef

Mirzaei H, Yazdi F, Salehi R, Mirzaei H. SiRNA and epigenetic aberrations in ovarian cancer. J Cancer Res Ther. 2016;12:498–508.CrossRef

Pourhanifeh M, Darvish M, Tabatabaeian J, Fard M, Mottaghi R, Azadchehr M, Jahanshahi M, Sahebkar A, Mirzaei H. Therapeutic role of curcumin and its novel formulations in gynecological cancers. J Ovarian Res. 2020;13:130.CrossRef

Rahimian N, Razavi Z, Aslanbeigi F, Mirkhabbaz A, Piroozmand H, Shahrzad M, Hamblin M, Mirzaei H. Non-coding RNAs related to angiogenesis in gynecological cancer. Gynecol Oncol. 2021;161:896–912.CrossRef

Vafadar A, Shabaninejad Z, Movahedpour A, Fallahi F, Taghavipour M, Ghasemi Y, Akbari M, Shafiee A, Hajighadimi S, Moradizarmehri S, Razi E, Savardashtaki A, Mirzaei H. Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell Biosci. 2020;10:32.CrossRef

Mirza M, Coleman R, González-Martín A, Moore K, Colombo N, Ray-Coquard I, Pignata S. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148–59.CrossRef

10.

Keeler ER, Das PM, Bast RC, Lu KH. Ovarian cancer screening. Amsterdam: ScienceDirect; 2010. pp. 87–107.

11.

Muinao T, Dekaboruah H, Pal M. Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells—an updated review. Exp Cell Res. 2017. https://doi.org/10.1016/j.yexcr.2017.10.018CrossRefPubMed

12.

Nossov V, Amneus M, Su F, Lang J, Janco J, Reddy ST, Farias-Eisner R. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol. 2008;199:215–23.CrossRef

13.

Hashemipour M, Boroumand H, Mollazadeh S, Tajiknia V, Nourollahzadeh Z, RohaniBorj M, Pourghadamyari H, Rahimian N, Hamblin M, Mirzaei H. Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers. Gynecol Oncol. 2021;161:314–27.CrossRef

14.

Razavi Z, Tajiknia V, Majidi S, Ghandali M, Mirzaei H, Rahimian N, Hamblin M, Mirzaei H. Gynecologic cancers and non-coding RNAs: epigenetic regulators with emerging roles. Crit Rev Oncol Hematol. 2021;157:103192.CrossRef

15.

Ali A, Zhang F, Maguire A, et al. HDAC6 degradation inhibits the growth of high-grade serous ovarian cancer cells. Cancers. 2020;12:3734.CrossRef

16.

Zhao H, Gao Y, Chen Q, Li J, Yue W. RAD51AP1 promote progression of ovarian cancer via TGF-β/Smad signaling pathway. SSRN J. 2019. https://doi.org/10.1111/jcmm.15877.CrossRef

17.

Chen L, Cai S, Wang JM, Huai YY, Chu Q. BRDT promotes ovarian cancer cell growth. Cell Death Dis. 2020. https://doi.org/10.1038/s41419-020-03225-yCrossRefPubMedPubMedCentral

18.

Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, Xu L, Luo T, Yan H, Long Z, Shi A. CancerSEA: a cancer single-cell state atlas. J Nucleic Acids Res. 2019. https://doi.org/10.1093/nar/gky939.CrossRef

19.

Charoentong P, Finotello F, Angelova M, Mayer C, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2016. https://doi.org/10.1016/j.celrep.2016.12.019CrossRef

20.

Bell D, Berchuck A, Birrer M, Chien J, Thomson E. Integrated genomic analyses of ovarian carcinoma TCGA Network. Nature. 2011;474:609–15. https://doi.org/10.1038/nature10166.CrossRef

21.

Liang L, Gao C, Yang L, Sun M, Zhao Y. MiR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway. Cell Death Dis. 2017;8:e2968.CrossRef

22.

Liang L, Xu J, Wang M, Xu G, Zhang N, Wang G, Zhao Y. LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. Cell Death Dis. 2018;9:372.CrossRef

23.

Wang L, Wang L, Ma L, Liu J, Ma S. Identifying gene signature for the detection of ovarian cancer based on the achieved related genes. Gynecol Obstet Invest. 2016. https://doi.org/10.1159/000449160CrossRefPubMed

24.

Sabatier R, Finetti P, Bonensea J, Jacquemier J, Adelaide J, Lambaudie E, Viens P, Birnbaum D, Bertucci F. A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer. 2011;105:304.CrossRef

25.

Mariathasan S, Turley SJ, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018.

26.

Trinidad CV, Tetlow AL, Bantis LE, Godwin AK. Reducing ovarian cancer mortality through early detection: approaches using circulating biomarkers. Cancer Prev Res. 2020;13:241–52.CrossRef

27.

Cochrane DR, Campbell KR, Greening K, Ho GC, Huntsman DGJ. Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. J Pathol. 2020. https://doi.org/10.1002/path.5511.CrossRefPubMed

28.

Liu L, Zhang P, Shao Y, Quan F, Li H. Knockdown of FOXJ1 inhibits the proliferation, migration, invasion, and glycolysis in laryngeal squamous cell carcinoma cells. J Cell Biochem. 2019;120:15874–82.CrossRef

29.

Abedalthagafi M, Wu M, Merrill P, Du Z, Woo T, Sheu S, Hurwitz S, Ligon K, Santagata S. Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol. 2016;238:584–97.CrossRef

30.

Torricelli F, Saxena A, Nuamah R, Neat M, Bille A. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy. Eur J Cancer. 2020;132:104–11.CrossRef

31.

Rahane C, Kutzner A, Heese K. A cancer tissue-specific FAM72 expression profile defines a novel glioblastoma multiform (GBM) gene-mutation signature. J Neuro Oncol. 2019;141:57–70.CrossRef

32.

Wang J, Cui F, Xiao W, Xue Y, Peng Z. Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer. J Exp Clin Cancer Res. 2015;34:13.CrossRef

33.

Zhang H, Ma R, Wang X, Su Z, Chen X, Shi D, Guo X, Liu H, Gao P. KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer. Oncogene. 2017;36:5609–19.CrossRef

34.

Gu S, Liang H, Qi D, Mao L, Mao G, Qian L, Zhang S. Knockdown of KIF26B inhibits breast cancer cell proliferation, migration, and invasion. OncoTargets Ther. 2018;11:3195–203.CrossRef

35.

Teng Y, Guo B, Mu X, Liu S. KIF26B promotes cell proliferation and migration through the FGF2/ERK signaling pathway in breast cancer. Biomed Pharmacother. 2018;108:766–73.CrossRef

36.

Li H, Shen S, Chen X, Ren Z, Li Z, Yu Z. miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway. Cancer Cell Int. 2019;19:205.CrossRef

37.

Kim S, Roh J, Lee H, Ryu M, Park Y, Park C. Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. Gastric Cancer. 2021;24:327–40.CrossRef

38.

Yuan S, Wang Y, Luo H, Jiang Z, Song S. Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis. Br J Haematol. 2020. https://doi.org/10.1111/bjh.16299.CrossRefPubMedPubMedCentral

39.

Hu D, Zhou M, Zhu X. Deciphering immune-associated genes to predict survival in clear cell renal cell cancer. BioMed Res Int. 2019;2019:2506843.PubMedPubMedCentral

40.

Yu L, Yang X, Xu C, Sun J, Fang Z, Pan H, Han W. Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer. Int Immunopharmacol. 2020;89:107077.CrossRef

41.

Kubon J, Sikic D, Eckstein M, Weyerer V, Stöhr R, Neumann A, Keck B, Wullich B, Hartmann A, Wirtz R, Taubert H, Wach S. Analysis of CXCL9, PD1 and PD-L1 mRNA in stage T1 non-muscle invasive bladder cancer and their association with prognosis. Cancers. 2020. https://doi.org/10.3390/cancers12102794.CrossRefPubMedPubMedCentral

42.

Chen Y, Zhang J, Gong W, Dai W, Xu X, Xu S. miR-588 is a prognostic marker in gastric cancer. Aging. 2020;13:2101–17.CrossRef

43.

Voiles L, Lewis D, Han L, Lupov I, Lin T, Robertson M, Petrache I, Chang H. Overexpression of type VI collagen in neoplastic lung tissues. Oncol Rep. 2014;32:1897–904.CrossRef

44.

Long R, Liu Z, Li J, Yu H. COL6A6 interacted with P4HA3 to suppress the growth and metastasis of pituitary adenoma via blocking PI3K-Akt pathway. Aging. 2019;11:8845–59.CrossRef

Title: Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer
Authors: Leilei Liang
Jian Li
Jing Yu
Jing Liu
Lin Xiu
Jia Zeng
Tiantian Wang
Ning Li
Lingying Wu
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02502-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/ β-catenin signaling pathway

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma

Identification of icaritin derivative IC2 as an SCD-1 inhibitor with anti-breast cancer properties through induction of cell apoptosis

Exosomal microRNAs shuttling between tumor cells and macrophages: cellular interactions and novel therapeutic strategies

DEPDC1B collaborates with GABRD to regulate ESCC progression

A novel signature derived from metabolism-related genes GPT and SMS to predict prognosis of laryngeal squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer